Cargando…
Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606961/ https://www.ncbi.nlm.nih.gov/pubmed/28660473 http://dx.doi.org/10.1007/s40273-017-0529-x |